EUVIMEDEUVIMED entdecken
Studienprotokoll

Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE)

Yusuke Sano iD, Masashi Kanai, Chigusa Morizane, Keita Sasaki iD, Michio Yoshimura, Yoshinori Ito, Junji Furuse, Masato Ozaka, Haruhiko Fukuda, Makoto Ueno, Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group

Japanese Journal of Clinical Oncology · 2024

DOI: 10.1093/jjco/hyae084 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Yusuke Sano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Drug Combinations, Nivolumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer remains a highly lethal disease with a 5-year survival proportion of <10%. Chemoradiotherapy is a treatment option for unresectable locally advanced (UR-LA) or borderline resectable (BR) pancreatic cancer, but its efficacy is not sufficient. Induction of the synergistic effect of irradiation and immune checkpoint inhibitors can be an attractive strategy. An open-label randomized phase III trial has been conducted since October 2020 to confirm the superiority of nivolumab plus S-1-based chemoradiotherapy over S-1-based chemoradiotherapy alone in patients with UR-LA or BR pancreatic cancer. A total of 216 patients will be enrolled in 14 institutions within 3.5 years. The primary endpoint of the safety run-in part is dose-limiting toxicity, and that of the phase III part is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCT2080225361 (https://jrct.niph.go.jp/latest-detail/jRCT2080225361).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDrug CombinationsNivolumabOxonic AcidPancreatic NeoplasmsTegafurAdultAgedFemaleHumansMaleMiddle AgedClinical Trials, Phase III as TopicImmune Checkpoint InhibitorsRandomized Controlled Trials as TopicEquivalence Trials as Topic

Stichwörter der Autor:innen

borderline resectablechemoradiotherapynivolumabpancreatic cancerunresectable locally advanced

Substanzen

Drug CombinationsImmune Checkpoint InhibitorsNivolumabOxonic AcidS 1 (combination)Tegafur

Autor:innen und Institutionen

  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Cancer Treatment Center, Kansai Medical University Hospital, Osaka 573-1191, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
  • Department of Radiation Oncology, Showa University School of Medicine, Tokyo 142-8666, Japan.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama 241-8515, Japan.

ORCID-Profile: Yusuke Sano, Keita Sasaki

Zitieren

APA

Sano, Y., Kanai, M., Morizane, C., Sasaki, K., Yoshimura, M., Ito, Y., Furuse, J., Ozaka, M., Fukuda, H., Ueno, M., & Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group (2024). Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae084

Vancouver

Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, et al. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae084

BibTeX
@article{Sano2024,
  author = {Sano, Yusuke and Kanai, Masashi and Morizane, Chigusa and Sasaki, Keita and Yoshimura, Michio and Ito, Yoshinori and Furuse, Junji and Ozaka, Masato and Fukuda, Haruhiko and Ueno, Makoto and Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group, Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group},
  title = {Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE)},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1093/jjco/hyae084}
}
Kostenlos starten →